Amyloidosis News and Research

RSS
Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.
Isis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients

Isis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Gene therapy transforms life for men with severe form of hemophilia B

Gene therapy transforms life for men with severe form of hemophilia B

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

HICCC receives $18 million grant from the National Cancer Institute

HICCC receives $18 million grant from the National Cancer Institute

Dynamic nuclear polarization: an interview with Professor Robert Griffin, Massachusetts Institute of Technology

Dynamic nuclear polarization: an interview with Professor Robert Griffin, Massachusetts Institute of Technology

Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Research findings could lead to new approach to Alzheimer’s prevention

Research findings could lead to new approach to Alzheimer’s prevention

Drugs that boost protein's production in neurons could help ward off Alzheimer's disease

Drugs that boost protein's production in neurons could help ward off Alzheimer's disease

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Royal Free London NHS Foundation Trust selects OpenText to manage scanned legacy case-notes

Royal Free London NHS Foundation Trust selects OpenText to manage scanned legacy case-notes

RNA interference approach holds great promise for treating cancer and other diseases

RNA interference approach holds great promise for treating cancer and other diseases

Early onset of dietary treatment may slow down progression of Alzheimer's disease

Early onset of dietary treatment may slow down progression of Alzheimer's disease

Early onset of dietary treatment may slow down progression of Alzheimer's, says research

Early onset of dietary treatment may slow down progression of Alzheimer's, says research

Study: Cholesterol levels linked to early signs of Alzheimer's disease in the brain

Study: Cholesterol levels linked to early signs of Alzheimer's disease in the brain

Diflunisal drug reduces neurological decline in patients with familial transthyretin amyloidosis

Diflunisal drug reduces neurological decline in patients with familial transthyretin amyloidosis

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR